跳到正文
原文
Medical Xpress·· 2026-10-13AI 评分49

小细胞肺癌干细胞样调控状态 SCLC-SL 与化疗免疫治疗后更短生存相关

Stem cell–like tumor state may help identify high-risk small-cell lung cancer

AI 导读

Northwestern Medicine 团队在 Cell Reports Medicine 发表研究,通过 ATAC-seq 分析染色质可及性,在小细胞肺癌中识别出此前未被认识的干细胞样调控状态 SCLC-SL,该亚型患者化疗免疫治疗后的中位总生存为 7.41 个月。

正文
New tumor state helps identify high-risk small-cell lung cancer
Credit: Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.103027

Northwestern Medicine scientists have identified a stem-like state in small-cell lung cancer that distinguishes a group of patients with exceptionally poor outcomes following chemoimmunotherapy, according to a study published in Cell Reports Medicine.

The findings could pave the way for new biomarkers and treatment strategies for one of the deadliest forms of lung cancer, said Anish Thomas, the Roswell Park professor of hematology and oncology and senior author of the study.

Small-cell lung cancer (SCLC) accounts for roughly 15% of lung cancer cases, according to estimates from the Centers for Disease Control and Prevention, and is characterized by rapid growth, early spread and frequent recurrence after treatment. Despite recent advances, clinicians have few tools to help determine which patients are most likely to have more aggressive cancers.

Mapping tumor-specific regulatory states

In the study, Thomas and his collaborators analyzed the chromatin landscape of SCLC, examining which regions of the genome were accessible to the tumor cells. The approach revealed a previously unrecognized tumor state, dubbed SCLC-SL, that appears particularly adaptable and is associated with poor treatment outcomes.

"We identified a previously unrecognized stem-like regulatory state of small-cell lung cancer by examining how DNA is packaged and which regions of the genome are accessible to the tumor cell," said Thomas, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "This state, which we call SCLC-SL, is less differentiated, metabolically adaptable and has reduced immune signaling compared with other SCLC states."

Most previous SCLC classification systems have relied on bulk gene-expression profiles. A limitation of this approach is that RNA measured from a tumor reflects a mixture of cancer cells and surrounding immune and stromal cells, making it difficult to distinguish tumor-intrinsic biology from differences in the tumor microenvironment. This may help explain why existing molecular classifications have not consistently separated patients according to clinical outcome.

To overcome this limitation, the investigators analyzed patient-derived xenograft tumors, which enabled tumor-specific regulatory signals to be distinguished from stromal signals, and used a technology called ATAC-seq to map chromatin accessibility, revealing which genes tumor cells are able to turn on. They then integrated the data with gene-expression profiles from more than 800 tumors across multiple patient cohorts.

The work revealed three major chromatin-defined regulatory states: a neuroendocrine state, an immune-active state and the newly discovered stem-like state. Tumors classified as SCLC-SL showed increased activity in biological processes associated with hypoxia, oxidative metabolism and cellular stress responses, and also exhibited reduced immune activity.

"We looked at which genes tumor cells can use. This revealed a biologically distinct stem-like state that was not fully captured by conventional SCLC classifications and was strongly associated with clinical outcome," Thomas said.

Stem-like tumors linked to shorter survival

Most notably, patients whose tumors were enriched for the stem-like state experienced substantially worse outcomes after chemoimmunotherapy. In a clinical trial cohort analyzed in the study, patients with SCLC-SL tumors had a median overall survival of 7.41 months, compared with 15.9 months for the immune-active subtype and 12.6 months for the neuroendocrine subtype. The association remained significant even after accounting for liver metastases, brain metastases and elevated lactate dehydrogenase levels (LDH), according to the study.

The findings represent one of the first molecular classifications of SCLC to distinguish patient outcomes even after accounting for established clinical risk factors, Thomas said.

"To our knowledge, this is one of the first studies to show that an SCLC molecular feature has independent prognostic significance after accounting for established clinical risk factors, including liver and brain metastases and serum levels of LDH," Thomas said.

Treatment may favor the stem-like state

The findings also suggest that SCLC tumors are more dynamic than previously appreciated.

"This shifts the way we think about SCLC subtypes," Thomas said. "Rather than viewing tumors as belonging to fixed categories, our data suggest that SCLC can occupy different regulatory states and potentially transition between them. That plasticity may be central to how these cancers adapt to treatment and develop resistance."

The investigators also found evidence that the stem-like state becomes more common after treatment. Analysis of matched patient samples collected before and after therapy showed enrichment of stemness following treatment, suggesting a more adaptable, treatment-resistant tumor type.

Testing a high-risk signature

While more research is needed to fully understand SCLC subtypes, the study establishes a potential framework for identifying patients at highest risk for poor outcomes and tailoring future therapies.

The biology of the newly identified state may also provide new therapeutic opportunities, Thomas said. The SCLC-SL state was associated with increased reliance on metabolic and stress-response pathways.

"If validated prospectively, a chromatin-informed signature could help identify patients whose tumors have this high-risk stem-like biology and who may be less likely to benefit from current approaches alone," Thomas said. "It could also help direct these patients toward clinical trials testing alternative strategies."

Looking ahead, the team plans to determine what drives tumors into the stem-like state and whether that process can be prevented or reversed.

"The next step is to validate this signature prospectively in patients and determine whether it can reliably identify patients with high-risk disease before treatment," said Thomas, who is also a member of the Center for Human Immunobiology (CHI). "We also want to understand what drives tumor cells into this stem-like state and whether we can therapeutically prevent or reverse it."

Publication details

Rajesh Kumar et al., A stem-like chromatin program in small-cell lung cancer is associated with poor outcomes after chemoimmunotherapy, Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.103027

Journal information: Cell Reports Medicine

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Stem cell–like tumor state may help identify high-risk small-cell lung cancer (2026, October 12) retrieved 12 October 2026 from https://medicalxpress.com/news/2026-10-stem-celllike-tumor-state-high.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com